Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23161884 | 0.87 | HRH1 (0.42) | PDE10AHRH1KCNH2CHRM1MAP4K4 | |
| SCHEMBL18057404 | 0.87 | PDE10A (0.39) | PDE10AHRH3HRH4MCHR1 | |
| SCHEMBL20078410 | 0.85 | DYRK1A (0.41) | PDE10AHRH1KCNH2CHRM1HRH3 | |
| SCHEMBL19365030 | 0.84 | SMN1; SMN2 (0.41) | PDE10AMAP4K4 | |
| SCHEMBL18057400 | 0.83 | MAP4K4 (0.39) | PDE10AMAP4K4HRH4 | |
| SCHEMBL17255025 | 0.82 | PDE10A (0.43) | PDE10AHRH1KCNH2CHRM1MAP4K4 | |
| SCHEMBL18057396 | 0.81 | HTR3A (0.48) | HRH3HRH4 | |
| SCHEMBL30287974 | 0.81 | PDE10A (0.41) | PDE10AHRH1KCNH2CHRM1MAP4K4 | |
| SCHEMBL19636369 | 0.81 | PDE10A (0.41) | PDE10AHRH1KCNH2CHRM1MAP4K4 | |
| SCHEMBL18057398 | 0.81 | PDE10A (0.37) | PDE10ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361937-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10442801-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| EP-3219716-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | Pimera, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9512123-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512123-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | PIMERA, INC | 2016-11-10 | — | — | US | disclosed |
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | PIMERA, INC | 2016-11-10 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326176-A1 | Novel Compositions, Uses and Methods for Making Them | BAX, CASP3, BCL2 | PDE10A 1165/4885HRH1 4375/4885KCNH2 3820/4885 |
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | PDE10A 848/4885HRH1 4378/4885KCNH2 3565/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | PDE10A 1165/4885HRH1 4375/4885KCNH2 3820/4885 |
| US-20200361937-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | PDE10A 1165/4885HRH1 4375/4885KCNH2 3820/4885 |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | PDE10A 1165/4885HRH1 4375/4885KCNH2 3820/4885 |
| US-10442801-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | PDE10A 848/4885HRH1 4378/4885KCNH2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.